VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Spyre Therapeutics, Inc. (SYRE) Total Return Calculator with Dividends Reinvested

Spyre Therapeutics, Inc.

Popular:

The total return for Spyre Therapeutics, Inc. (SYRE) stock is +483.53% over the past 12 months. So far it's up 138.72% this year. The 5-year total return is -59.95%, meaning $10,000 invested in SYRE stock 5 years ago would be worth $4,005 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in SYRE 1 year ago, it would be worth $57,514 today — you'd have gained $47,514.

With Dividends Reinvested$57,514+475.14%

Price Only (No DRIP)$57,514+475.14%

Period2025-05-07 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in SYRE

1Y$58,353+$48,353 (+483.5%)483.5% CAGR

3Y$184,810+$174,810 (+1748.1%)164.4% CAGR

5Y$4,005-$5,995 (-59.9%)-16.7% CAGR

10Y$3,352-$6,648 (-66.5%)-10.4% CAGR

15Y$2,989-$7,011 (-70.1%)-7.7% CAGR

20Y$2,989-$7,011 (-70.1%)-5.9% CAGR

30Y$2,989-$7,011 (-70.1%)-3.9% CAGR

Spyre Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading SYRE total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+138.72%	—	+138.72%	—	$23,872
1Y	+483.53%	483.53%	+483.53%	—	$58,353
3Y	+1748.10%	164.39%	+1748.10%	—	$184,810
5Y	-59.95%	-16.72%	-59.95%	—	$4,005
10Y	-66.48%	-10.35%	-66.48%	—	$3,352
15Y	-70.11%	-7.74%	-70.11%	—	$2,989
20Y	-70.11%	-5.86%	-70.11%	—	$2,989
30Y	-70.11%	-3.95%	-70.11%	—	$2,989

Risk & Highlights

Best Year+104.37%2023

Worst Year-90.57%2022

Max Drawdown-20.91%2025-06-10 → 2025-06-23 · Recovered 2025-10-09

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+40.65%	+40.65%	—	+0.41%	+40.2pp
2025	+37.36%	+37.36%	—	+16.64%	+20.7pp
2024	+8.79%	+8.79%	—	+24.00%	-15.2pp
2023	+104.37%	+104.37%	—	+24.81%	+79.6pp
2022	-90.57%	-90.57%	—	-19.95%	-70.6pp

SYRE outperformed the S&P 500 by 452.21pp over the past year (+483.53% vs +31.32%).

Loading summary...

SYRE Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
SYRESpyre Therapeutics, Inc.	$25.3B	+49.0%	+138.7%	+483.5%	—	+1748.1%	-59.9%	-66.5%
ARRYArray Technologies, Inc.	$1.3B	+16.5%	-16.1%	+57.7%	—	-56.5%	-68.0%	-77.7%
PRTAProthena Corporation plc	$567M	+11.4%	+21.5%	+52.1%	—	-85.5%	-52.7%	-70.8%
TRMBTrimble Inc.	$14.7B	-2.5%	-19.0%	+0.2%	—	+33.4%	-16.5%	+172.8%
PTGXProtagonist Therapeutics, Inc.	$6.3B	+1.0%	+19.3%	+147.5%	—	+317.0%	+271.1%	+788.6%
TERNTerns Pharmaceuticals, Inc.	$4.6B	+0.4%	+32.1%	+1659.7%	—	+302.8%	+229.8%	+188.0%
JANXJanux Therapeutics, Inc.	$878M	-2.1%	+7.1%	-42.8%	—	+6.6%	-41.9%	-41.9%
ABBVAbbVie Inc.	$358.4B	-0.8%	-9.1%	+13.1%	+3.6pp	+52.0%	+102.8%	+306.7%
JNJJohnson & Johnson	$536.2B	-6.8%	+9.0%	+48.8%	+3.4pp	+47.6%	+48.0%	+136.2%
LLYEli Lilly and Company	$921.2B	+6.5%	-8.5%	+28.2%	+0.8pp	+131.9%	+421.4%	+1271.7%
REGNRegeneron Pharmaceuticals, Inc.	$73.7B	-5.5%	-7.0%	+29.7%	+0.6pp	-3.6%	+45.4%	+96.0%

Compare:SYRE vs ARRY SYRE vs PRTA SYRE vs TRMB SYRE vs ARRY vs PRTA

About SYRE Dividend Returns

Spyre Therapeutics, Inc. (SYRE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of SYRE over the past year?

Spyre Therapeutics, Inc. (SYRE) delivered a return of 483.53% over the past year. Since SYRE does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in SYRE be worth today?

A $10,000 investment in Spyre Therapeutics, Inc. one year ago would be worth $58,353 today, representing a gain of $48,353.

Q3Does SYRE pay dividends?

Spyre Therapeutics, Inc. (SYRE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For SYRE, the total return equals the price-only return.

Q4Did SYRE beat the S&P 500?

Yes, Spyre Therapeutics, Inc. (SYRE) outperformed the S&P 500 by 452.21 percentage points over the past year. SYRE delivered a total return of 483.53%, compared to the S&P 500's 31.32%. This 452.21pp alpha means investors in SYRE earned more than a passive S&P 500 index fund.

Q5What is SYRE's worst drawdown?

Spyre Therapeutics, Inc. (SYRE) experienced a maximum drawdown of -20.91% over the past year, declining from its peak on 2025-06-10 to its trough on 2025-06-23. The stock recovered to its prior peak by 2025-10-09. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is SYRE's long-term total return over 10, 20, or 30 years?

Here are Spyre Therapeutics, Inc. (SYRE)'s long-term returns with dividends reinvested. Over 10 years, the total return is -66.5% (-10.4% CAGR) — $10,000 would have grown to $3,352. Over 20 years: -70.1% total return (-5.9% CAGR) — $10,000 → $2,989. Over 30 years: -70.1% total return (-3.9% CAGR) — $10,000 → $2,989. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was SYRE's best and worst year?

Spyre Therapeutics, Inc.'s best calendar year was 2023 with a total return of 104.4%. Its worst year was 2022 with a total return of -90.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 194.9 percentage points.